



CMIC has been presented the 2007 Frost & Sullivan Best Practices Award

CMIC has been presented the 2007 Frost & Sullivan Best Practice Award for Competitive Strategy Leadership Award in the Japanese Contract Research Organization Market.

Frost & Sullivan Best Practices Awards are presented to companies in recognition of making an outstanding contribution to their respective industry or achieving a competitive or customer-based leading position in the market.

“In an increasingly competitive CRO market, the need to build enduring customer relationships cannot be stressed enough. Delivering value to customers businesses is imperative as the need for cost and process efficiencies fuel the growth of the Clinical Research sector.”

“In this scenario, CMIC has implemented focused strategies to add value to their Clients’ businesses. These steps include the delivery of a total solution aimed at maximizing value for Pharmaceutical companies as well as enhancement of infrastructure to support their services. CMIC’s initiatives have worked not only towards contributing to the establishment of Evidence Based Medicine for their Clients, but also helped their own business grow significantly in Japan and be recognized among the key players in the Japan CRO industry” says Frost & Sullivan’s Manager - Growth Partnership Services, Sohini Mitra

About Frost & Sullivan

Founded in 1961, Frost & Sullivan, a global leader in growth consulting, presents its awards to companies that demonstrate excellence in their industry, commending the diligence and innovative business strategies required to advance in the global marketplace. Frost & Sullivan rigorously analyzes specific criteria to determine award recipients in a vast variety of market industries and landscapes. For further information, visit: www.frost.com

About CMIC

Since 1992, CMIC has supported such drug development-related activities as monitoring, data management, recruiting of test subjects and clinical test coordination as Japan's first CRO (Contract Research Organization). Capitalizing on the long years of experience and know-how as a CRO, it engages mainly in PVC (Pharmaceutical Value Creator) activities including CMO (Contract Manufacturing Organization) and CSO (Contract Sales Organization), in support of the value chains of pharmaceutical companies. CMIC has a presence not only in Japan but in Asia (China, Korea, Singapore and Taiwan), Brazil and U.S.A, and engages in a wide range of activities.

For further information, visit: www.cmic.co.jp